Publication: International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV
| dc.contributor.author | Singer, Susanne (8044967900) | |
| dc.contributor.author | Amdal, Cecilie Delphin (35482981700) | |
| dc.contributor.author | Hammerlid, Eva (6601966076) | |
| dc.contributor.author | Tomaszewska, Iwona M. (55702103400) | |
| dc.contributor.author | Castro Silva, Joaquim (55509889400) | |
| dc.contributor.author | Mehanna, Hisham (11839081200) | |
| dc.contributor.author | Santos, Marcos (56276517700) | |
| dc.contributor.author | Inhestern, Johanna (55243353800) | |
| dc.contributor.author | Brannan, Christine (57191847313) | |
| dc.contributor.author | Yarom, Noam (8317667000) | |
| dc.contributor.author | Fullerton, Amy (18634351100) | |
| dc.contributor.author | Pinto, Monica (55338042000) | |
| dc.contributor.author | Arraras, Juan I. (6701753532) | |
| dc.contributor.author | Kiyota, Naomi (23492603200) | |
| dc.contributor.author | Bonomo, Pierluigi (54911583000) | |
| dc.contributor.author | Sherman, Allen C. (7201763995) | |
| dc.contributor.author | Baumann, Ingo (7006255873) | |
| dc.contributor.author | Galalae, Razvan (6701597227) | |
| dc.contributor.author | Fernandez Gonzalez, Loreto (56625967900) | |
| dc.contributor.author | Nicolatou-Galitis, Ourania (6701317806) | |
| dc.date.accessioned | 2025-06-12T15:12:55Z | |
| dc.date.available | 2025-06-12T15:12:55Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life. © 2019 Wiley Periodicals, Inc. | |
| dc.identifier.uri | https://doi.org/10.1002/hed.25609 | |
| dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059916248&doi=10.1002%2fhed.25609&partnerID=40&md5=537d9198015ccfc47499f3362d51ddbc | |
| dc.identifier.uri | https://remedy.med.bg.ac.rs/handle/123456789/5581 | |
| dc.subject | chemoradiation | |
| dc.subject | head and neck cancer | |
| dc.subject | multimodal therapies | |
| dc.subject | quality of life | |
| dc.subject | validation | |
| dc.title | International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV | |
| dspace.entity.type | Publication | |
